GlassScriptPhysician profile
Maxwell C Mcdonald
NPI 1699764589
$123,210.86
in general payments reported to CMS, 2019-2025
39 companies · $944 in 2025
The $944 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $13K · 2021: $21K · 2022: $28K · 2023: $5,642 · 2024: $3,922 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,930 · Food and Beverage: $1,860 · Long Term Medical Supply Or Device Loan: $1,598 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,930.00 |
| Food and Beverage | $1,859.86 |
| Long Term Medical Supply Or Device Loan | $1,598.16 |
| Education | $120.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $70,131.01 | 2019-2025 | Lynparza, Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $33,791.88 | 2019-2023 | Keytruda, Lynparza |
| Genentech USA, INC. | $14,564.37 | 2019-2023 | Tecentriq, Venclexta |
| Novartis Pharmaceuticals Corporation | $2,024.83 | 2019-2025 | |
| Abbvie INC. | $387.19 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $237.62 | 2022-2023 | Precisetumor |
| Genmab U.S., INC. | $229.17 | 2023-2024 | Tivdak |
| Takeda Pharmaceuticals U.S.A., INC. | $219.22 | 2019-2021 | |
| Janssen Biotech, INC. | $198.23 | 2019-2023 | Erleada |
| Pfizer INC. | $194.46 | 2019-2024 | |
| Daiichi Sankyo INC. | $178.16 | 2019-2025 | Enhertu |
| Seagen INC. | $99.99 | 2025 | |
| Incyte Corporation | $97.79 | 2019-2024 | Jakafi |
| Amgen INC. | $85.86 | 2019-2023 | Nplate, Xgeva, Vectibix |
| E.R. Squibb & Sons, L.L.C. | $65.24 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $61.07 | 2023 | Imbruvica, Epkinly |
| Celgene Corporation | $57.59 | 2019 | |
| Tempus Ai, INC | $56.95 | 2025 | Xt Cdx |
| Exelixis INC. | $54.09 | 2019 | |
| Glaxosmithkline, LLC. | $48.23 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.14 | 2019 | |
| Gilead Sciences, INC. | $41.83 | 2019-2021 | |
| Mirati Therapeutics, INC. | $39.96 | 2023 | Krazati |
| Astellas Pharma US INC | $32.33 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $24.33 | 2019 | |
| Rigel Pharmaceuticals, INC. | $22.81 | 2019 | |
| Genzyme Corporation | $21.05 | 2019 | |
| Tesaro, INC. | $20.06 | 2019 | |
| Taiho Oncology, INC. | $19.05 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.86 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $18.42 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.59 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.56 | 2019 | |
| Partner Therapeutics, INC. | $16.50 | 2019 | |
| Lilly USA, LLC | $16.13 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.52 | 2019 | |
| Clovis Oncology, INC. | $15.52 | 2019 | |
| Eisai INC. | $15.32 | 2023 | |
| Acrotech Biopharma INC. | $13.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxwell Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.